# US 2021/0340525 A1 · Genetically-encoded bicyclic peptide libraries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340525 A1
- Document ID: US20210340525A1
- Status: Published application
- Kind: A1
- Application number: 17/261,390
- Filed: 2019-07-23
- Published: 2021-11-04
- Earliest claimed: 2018-07-23
- Assignees: The Governors of the University of Alberta
- Applicants: The Governors of the University of Alberta
- Inventors: Ratmir DERDA; Raja MUKHERJEE; Vivian TRIANA
- Web page: https://patentgrep.com/patent/US20210340525A1

## CPC

- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- C40B 40/10: Libraries containing peptides or polypeptides, or derivatives thereof
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The invention relates to a bicyclic peptide complex comprising a peptide construct, said construct comprising (i) a polypeptide with free terminus (N or C); (ii) optionally, a nucleic acid encoding the polypeptide; (iii) a twofold-symmetric linker (TSL) compound attached to said polypeptide where the linker is attached to the terminus of polypeptide via a covalent bond and to at least two discrete side chains of the peptide. The invention also relates to libraries, and to methods for making complexes and to methods of screening using the same.

## Claims

### Claim 1

A peptide construct comprising a bicyclic structure resulting from attaching a linker having a first end and a second end comprising two reactive groups to a polypeptide, wherein the first end is ligated to a terminus of the polypeptide by a covalent bond, and wherein both reactive groups of the linker second end are each reacted to side chain residues of the polypeptide.

### Claim 2 (depends on 1)

The construct of claim 1 wherein the two second end reactive groups are identical.

### Claim 3 (depends on 1)

The construct of claim 1 wherein the polypeptide terminus is an N-terminus and the side chain residues are cysteine, lysine or tyrosine.

### Claim 4 (depends on 1)

The construct of claim 1 wherein the linker reactive groups are electrophilic groups reactive to thiol, amine or phenol.

### Claim 5 (depends on 1)

The construct of claim 1 wherein the linker first end comprises an aldehyde reactive group comprising an oxime, hydrazine, 2-amino benzamidoxime, phosphonium ylide, sulphur ylide, nitrogen ylides or any other carbon nucleophile and carbenoid reagent known to be reactive with aldehydes and stable in aqueous environment.

### Claim 6 (depends on 1)

The construct of claim 1 wherein the polypeptide comprises two cysteine residues and an N-terminal serine or threonine residue, wherein the N-terminal serine or threonine is first converted to an aldehyde by selective oxidation and wherein the second end reactive groups are covalently bonded to the cysteine residues.

### Claim 7 (depends on 1)

The construct of claim 1 which is attached to a carrier comprising a phage particle bearing the polypeptide externally and including a nucleic acid encoding the polypeptide.

### Claim 8 (depends on 1)

The construct of claim 1 which is a RNA display compound, said RNA display bearing the polypeptide; and including an RNA sequence encoding the polypeptide, and linked to the polypeptide.

### Claim 9 (depends on 1)

The construct of claim 1 which is a DNA display compound, said DNA display bearing the polypeptide; and including a DNA encoding the polypeptide, linked to the polypeptide.

### Claim 10 (depends on 1)

The construct of claim 1 wherein the polypeptide terminus is a C-terminus and the side chain residues are cysteine or lysine, and wherein the linker first end comprises a reactive group with reactivity to C-terminus in acidic pH and the linker second end comprises two electrophilic groups that react specifically with thiol or amine residues.

### Claim 11 (depends on 10)

The construct of claim 10 wherein the reactive group with reactivity to C-terminus in acidic pH is a C-terminal-selective photoredoxdecarboxylative conjugate addition.

### Claim 12 (depends on 4)

The construct of claim 4 wherein the linker electrophilic groups are groups reactive with thiol in water comprising haloketone, haloacetamide, halobenzyl, a Michael acceptor comprising a conjugated C—C double bond including maleimides, actylates, carbonylacrylic reagents, 3-arylpropiolonitriles, allenamides fluoroarene, chlorotetrazines, Julia-Kocienśki-like reagents, 2-azidoacrylates, organometallic palladium reagents, organo gold(I) reagents, conversion of thiols to dehydroalanines (Dha) followed by conjugate addition to Dha.

### Claim 13 (depends on 4)

The construct of claim 4 wherein the linker electrophilic groups are groups reactive with amine in water comprising N-hydroxysuccinimide esters, aryl esters, perfluoroaryl esters, perfluoroarenes, ketenes, ortho-phthalaldehydes, or strain-release amine modifying agents.

### Claim 14 (depends on 10)

The construct of claim 10 wherein the linker electrophilic groups are groups reactive with phenol in water comprising allylpaladium, diazodicarboxylate, diazonium salts, aniline-formaldehyde hemiaminal, rhodium carbenoids, dirhodium metallopeptide catalysts, Manganese-Catalyzed C—H Alkynylation, Waser's reagent, 1-[(triisopropylsilyl)ethynyl]-1,2-benziodoxol-3(1H)-one (TIPS-EBX), under gold(I) catalysis, selective ruthenium-(II)-catalyzed C—H activation, palladium (II) acetate catalyzed C—H activation with aryl iodides in water.

### Claim 15 (depends on 1)

The construct of claim 1 wherein the polypeptide comprises a terminal serine residue and two cysteine residues separated by at least 2, 3, 4 or 5 amino acid residues.

### Claim 16 (depends on 1)

The construct of claim 1 wherein the linker comprises an alkyl chain having between 1-6 carbon atoms.

### Claim 17 (depends on 1)

The construct of claim 1 wherein the polypeptide comprises only natural proteogenic amino acids and/or which does not comprise free N-terminus.

### Claim 18

A method for making a phage display complex, said method comprising (i) providing a phage particle comprising a polypeptide having a terminus (ii) providing a linker having a first end and a second end comprising two reactive groups, and forming an intermediate complex by ligating the linker first end with the polypeptide terminus to form a covalent bond, and (iii) forming a bicyclic structure from the intermediate complex by reacting both reactive groups of the linker second end to side chain residues of the polypeptide.

### Claim 19 (depends on 18)

The method of claim 18 wherein steps (ii) and (iii) are independent and sequential.

### Claim 20 (depends on 18)

The method of claim 18 wherein steps (ii) and (iii) are performed at different pHs.

### Claim 21 (depends on 18)

The method of claim 18 wherein the terminus of the polypeptide is an N-terminus and is oxidized to aldehyde before the ligation step, and wherein the ligation step comprises mixing the polypeptide comprising N-terminal aldehyde with the linker in aqueous buffer of acidic pH.

### Claim 22 (depends on 18)

The method of claim 18 wherein the intermediate complex is purified, such as by size-exclusion purification, such as by gel filtration or dialysis in aqueous buffer of acidic pH, such as below about pH 5.

### Claim 23 (depends on 22)

The method of claim 22 wherein the purified intermediate complex is reduced with a reducing agent such as TCEP (“reduction step”), prior to the bicyclization step.

### Claim 24 (depends on 23)

The method of claim 23 wherein the reduced intermediate complex is exposed to pH of 7 or above to induce bicyclization, wherein the second end reactive groups each comprise a thiol-reactive group and the polypeptide comprises two cysteine residues.

### Claim 25 (depends on 18)

The method of claim 18 comprising the further steps of exposing the polypeptide to a capture reagent which is reactive to unreacted polypeptide but not reacted polypeptide and measuring the incorporation of capture agent with an affinity reagent.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 1)

A genetically encoded library of ligands comprising a plurality of different peptide sequences forming a bicyclic structure as described in claim 1.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 1)

A method for identifying a complex of claim 1 which is capable of binding to a ligand, the method comprising (i) contacting a library of complexes with the ligand, and (ii) selecting those complexes which bind to the ligand (iii) identifying the structure of a binding complex by sequencing a nucleic acid that encodes the structure of peptide and/or linker.

### Claim 38

(canceled)

### Claim 39

(canceled)
